ArticleThe Journal of clinical investigation2001
Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Article in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.Pharmacology research & perspectives · 2025Article
- Engineered CD4 T cells for in vivo delivery of therapeutic proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.Journal for immunotherapy of cancer · 2022Article
- Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.Molecular therapy oncolytics · 2021Article
- APN-mediated phosphorylation of BCKDK promotes hepatocellular carcinoma metastasis and proliferation via the ERK signaling pathway.Cell death & disease · 2020Article
- Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.Cancer science · 2020Article
- Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.Journal of neuro-oncology · 2018Article
- Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis.British journal of cancer · 2018Article
- Article
- Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells.Cancer gene therapy · 2012Article
- Using lentiviral vectors for efficient pancreatic cancer gene therapy.Cancer gene therapy · 2010Article
- Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.PLoS medicine · 2007Article
- Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma.Cancer gene therapy · 2006Article
- Gene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agents.Cancer gene therapy · 2005Article
- Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.British journal of cancer · 2005Article
- Anti-tumor effect of pEgr-IFNgamma gene-radiotherapy in B16 melanoma-bearing mice.World journal of gastroenterology · 2004Article
- Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model.Cancer gene therapy · 2003Article
- Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.Oncogene · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Most patients succumbing to colorectal cancer fail with liver-predominant metastases. To make a clinical impact in this disease, a systemic or whole-liver therapy may be required, whereas most cancer gene therapy approaches are limited in their ability to treat beyond local disease. As a preclinical model for cancer gene therapy, recombinant adenovirus containing the human IFN-beta (hIFN-beta) cDNA was delivered systemically in nude mouse xenograft models of human colorectal cancer liver metastases. The vector targeted hepatocytes that produced high levels of hIFN-beta in the liver, resulting in a profound apoptotic response in the tumors and significant tumor regression. hIFN-beta gene therapy not only resulted in improved survival and long-term cure in a micrometastatic model, but provided similar benefits in a clinically relevant gross disease model. A similar recombinant adenovirus containing the murine IFN-beta (mIFN-beta) cDNA also resulted in a therapeutic response and improved survival in syngeneic mouse models of colorectal cancer liver metastases. Depletion studies demonstrate a contribution of natural killer cells to this therapeutic response. The toxicity of an adenoviral vector expressing murine IFN-beta in a syngeneic model is also presented. These encouraging results warrant further investigation of the use of cancer gene therapy for targeting metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.